Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reoperative retroperitoneal surgery.

Joel Sheinfeld1, Pramod Sogani

  • 1Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. sheinfej@mskcc.org

The Urologic Clinics of North America
|May 9, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Can Novel Biomarkers Augment Traditional Surveillance Paradigms in Early-stage Testicular Germ Cell Tumors? A Case Study in Pre-clinical Relapse Detection Using a Combination Micro-RNA-371a-3p and 372-3p Assay.

Urology·2025
Same author

Validation of the Testicular Health Outcomes Report (THOR): a testicular cancer health-related quality of life instrument.

BJU international·2025
Same author

Baseline health-related quality-of-life metrics among patients with testicular germ cell tumours.

BJU international·2025
Same author

ASO Visual Abstract: Clinicopathologic Characteristics and Clinical Outcomes of Patients with Testicular Mesothelioma.

Annals of surgical oncology·2025
Same author

Pathologic and Oncologic Outcomes of Patients Undergoing Orchiectomy After Chemotherapy for Advanced Testicular Germ Cell Tumors.

European urology open science·2025
Same author

Clinicopathologic Characteristics and Clinical Outcomes of Patients with Testicular Mesothelioma.

Annals of surgical oncology·2025
Same journal

An Unprecedented Era of Innovation in Non-Muscle-Invasive Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Hubert Humphrey's Bladder Cancer: If He Could Have Time Traveled, Would that Have Changed the Outcome?

The Urologic clinics of North America·2026
Same journal

Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management.

The Urologic clinics of North America·2026
Same journal

Future Directions: Artificial Intelligence and Digital Tools in Bladder Cancer Care.

The Urologic clinics of North America·2026
Same journal

Economic Considerations in the Management of Superficial Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care.

The Urologic clinics of North America·2026
See all related articles

Radical prostatectomy lymph node dissection (RPLND) must be done with therapeutic intent for best outcomes. Reoperative surgery combined with chemotherapy offers nearly 70% survival for patients with retroperitoneal relapse after initial suboptimal RPLND.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Urologic Oncology

Background:

  • Retroperitoneal lymph node dissection (RPLND) is a critical diagnostic and therapeutic procedure in managing testicular cancer.
  • The adequacy of the initial RPLND significantly impacts patient prognosis and clinical outcomes.
  • Chemotherapy may not fully compensate for inadequate surgical resection in initial RPLND.

Purpose of the Study:

  • To evaluate the prognostic significance of initial RPLND adequacy.
  • To assess the role of modified templates in primary RPLND and post-chemotherapy RPLND (PC-RPLND).
  • To determine the outcomes of reoperative RPLND in patients with retroperitoneal relapse after suboptimal initial surgery.

Main Methods:

  • Review of cases undergoing primary RPLND or PC-RPLND.

Related Experiment Videos

  • Analysis of outcomes based on the adequacy of initial RPLND.
  • Evaluation of reoperative RPLND in patients with residual or recurrent disease, including teratomatous elements.
  • Integration of chemotherapy with reoperative surgery.

    • Main Results:

    • Suboptimal initial RPLND is associated with unresected disease, even with modified templates.
    • Anatomical mapping studies for modified templates have limitations.
    • Reoperative RPLND in experienced centers has acceptable morbidity.
    • Combined chemotherapy and reoperative surgery achieve nearly 70% survival in patients with retroperitoneal relapse post-suboptimal RPLND.

    Conclusions:

    • Therapeutic intent is crucial for initial RPLND success.
    • Modified templates may lead to incomplete resection.
    • Reoperative RPLND, especially when combined with chemotherapy, is a viable option for managing retroperitoneal relapse after initial suboptimal surgery.